World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
71
Citations
25810
World Ranking
2277
National Ranking
204

Angus G. Dalgleish publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Angus G. Dalgleish sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 387 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Angus G. Dalgleish D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Angus G. Dalgleish sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 71 D-Index — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Angus G. Dalgleish is affiliated with St George's, University of London in the United Kingdom. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a significant focus on oncology and immunology subfields. They have contributed to the study of Oncology, Immunology, Molecular Biology, Infectious Diseases, and Cancer Research.

Their main research topics include:

  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Pancreatic and Hepatic Oncology Research
  • Immune Cell Function and Interaction
  • CAR-T cell therapy research
  • SARS-CoV-2 and COVID-19 Research
  • Monoclonal and Polyclonal Antibodies Research

Dalgleish has published multiple papers across well-known venues. Frequent publication venues include:

  • Oncology Reports
  • Frontiers in Immunology
  • Oncology Letters
  • Cancer Research
  • Journal for ImmunoTherapy of Cancer

Selected recent papers authored or co-authored by Dalgleish include:

  • Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma, 2020, Journal for ImmunoTherapy of Cancer
  • Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity, 2020, QRB Discovery
  • Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends", 2020, Frontiers in Immunology
  • Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy, 2021, Vaccines
  • Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells, 2020, Clinical & Translational Oncology

Among frequent collaborators, Dalgleish has worked extensively with Satvinder Mudan, Helmout Modjtahedi, Peter L. Smith, Alan M. Seddon, and Said Khelwatty. Collaboration with these researchers is demonstrated by multiple joint publications.

Best Publications

  • The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

    Angus G. Dalgleish;Peter C. L. Beverley;Paul R. Clapham;Dorothy H. Crawford

  • The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

    Paul Jay Maddon;Angus G. Dalgleish;J.Steven McDougal;Paul R. Clapham

  • The evolution of thalidomide and its IMiD derivatives as anticancer agents

    J. Blake Bartlett;Keith Dredge;Angus G. Dalgleish

  • Slim disease: a new disease in Uganda and its association with HTLV-III infection.

    D. Serwadda;N.K. Sewankambo;J.W. Carswell;A.C. Bayley

  • Chronic immune activation and inflammation as the cause of malignancy.

    Kenneth J. O'Byrne;A. G. Dalgleish

  • Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

    Robin A. Weiss;Paul R. Clapham;Rachanee Cheingsong-Popov;Angus G. Dalgleish

  • Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells

    Paul R. Clapham;Jonathan N. Weber;Denise Whitby;Kenneth McIntosh;Kenneth McIntosh

  • Epitopes of the CD4 antigen and HIV infection.

    Quentin J. Sattentau;Angus G. Dalgleish;Robin A. Weiss;Peter C. L. Beverley

  • Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

    Dredge K;Marriott Jb;Macdonald Cd;Man Hw

  • The use of 7-amino actinomycin D in identifying apoptosis : Simplicity of use and broad spectrum of application compared with other techniques

    N. J. Philpott;A. J. C. Turner;J. Scopes;M. Westby

  • The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

    Christine Galustian;Brendan Meyer;Marie-Christine Labarthe;Keith Dredge

  • Variable and conserved neutralization antigens of human immunodeficiency virus

    Robin A. Weiss;Paul R. Clapham;Jonathan N. Weber;Angus G. Dalgleish

  • Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.

    Keith Dredge;Rebecca Horsfall;Simon P. Robinson;Ling-Hua Zhang

  • Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

    Unknown

  • Origins of HIV and the evolution of resistance to AIDS.

    Jonathan L. Heeney;Angus G. Dalgleish;Robin A. Weiss

  • HIV infection does not require endocytosis of its receptor, CD4.

    Paul Jay Maddon;J. Steven McDougal;Paul R. Clapham;Angus G. Dalgleish

  • Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

    Unknown

  • PREVALENCE OF ANTIBODY TO HUMAN T-LYMPHOTROPIC VIRUS TYPE III IN AIDS AND AIDS-RISK PATIENTS IN BRITAIN

    R Cheingsong-Popov;R.A Weiss;A Dalgleish;R.S Tedder

  • The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease.

    Kenneth J. O'Byrne;A. G. Dalgleish;M. J. Browning;W. P. Steward

  • Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

    J B Bartlett;A Michael;I A Clarke;K Dredge

  • Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer.

    Angus G Dalgleish;Ken J O'Byrne

  • Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester.

    Paul R. Clapham;Robin A. Weiss;Angus G. Dalgleish;Mark Exley

  • Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity

    Keith Dredge;J. Blake Marriott;Stephen M. Todryk;George W. Muller

Frequent Co-Authors

Stephen Todryk
Stephen Todryk Northumbria University
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
Paul R. Clapham
Paul R. Clapham University of Massachusetts Chan Medical School
William P. Steward
William P. Steward University of Leicester
Peter Smith
Peter Smith University of Aberdeen
Mark R. Middleton
Mark R. Middleton University of Oxford
Christian H. Ottensmeier
Christian H. Ottensmeier University of Southampton
Robin A. Weiss
Robin A. Weiss University College London
Jonathan L. Heeney
Jonathan L. Heeney University of Cambridge
Paul Lorigan
Paul Lorigan University of Manchester

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related degrees such as nursing can open diverse career pathways. Many students look for the easiest nurse practitioner program to balance rigorous study with personal commitments, ensuring a smoother transition into healthcare roles.

Specializations like psychiatric nursing are also popular, with some of the best psychiatric mental health nurse practitioner programs online offering strong clinical placement rates that provide invaluable hands-on experience for future practitioners.

Cost is a significant consideration for many students. Fortunately, several affordable options exist; exploring cheap psych np programs can help reduce financial barriers while still offering quality education and career readiness.

Graduates pursuing advanced nursing degrees like the Doctor of Nursing Practice (DNP) often benefit from competitive salaries. Understanding the doctor of nursing practice salary by state can guide career decisions and geographic preferences for employment.

Best Scientists Citing Angus G. Dalgleish

Trending Scientists

Recently Published Articles